Pending merger transaction between Grifols, Talecris has been extended

NewsGuard 100/100 Score

Grifols S.A. (GRF.MC) and Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that the outside date under their merger agreement for closing their pending merger transaction has been extended to June 30, 2011 (from March 6, 2011). Grifols has extended the financing and financing commitments from its lenders to June 30, as well. Grifols is continuing to work with the U.S. Federal Trade Commission to obtain its clearance of the proposed transaction. As previously disclosed, Grifols has agreed with FTC not to close the merger transaction without providing to the FTC at least thirty days advanced notice.

Source:

Talecris Biotherapeutics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stem cell therapy trial shows promise for regenerative treatment of heart failure